Best in Biotech 4 Nov 2022 Get to know 15 of the best biotech companies in Paris Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In this guide, we explore 15 interesting biotech companies in Paris. Paris is one of the biggest biotech clusters in Europe, with a wide range of applications being developed from drug discovery and medical devices to synthetic biology and green energy. […] November 4, 2022 - 11 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2021 Gene-Edited T Cell Therapy Players Battle Safety Doubts Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused all clinical development following the detection of an unexpected genetic change in a clinical trial. Industry experts see these events as a reality check for the nascent field. Off-the-shelf treatments that use genetically engineered T cells to treat diseases suffered […] October 22, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2021 A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […] October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2021 European Cancer Deals Increasingly Focus on Natural Killer Cells Natural killer cells are becoming a hot topic in the booming cancer cell therapy scene, with the field’s latest big deal being a €640M licensing agreement between the French biotech Cellectis and US company Cytovia. T-cell immunotherapies like CAR T-cell therapy have revolutionized cancer treatment in recent times. However, they have a significant disadvantage. The […] February 23, 2021 - 6 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2020 Covid-19 Leaves Lasting Impact on Hematology at ASH 2020 Conference Under the heavy shadow of the Covid-19 pandemic, last week’s annual conference of the American Society of Hematology (ASH) displayed the achievements of many innovative treatments for blood conditions, including gene and cell therapies. A sweeping new wave of Covid-19 infections that is forcing new lockdowns across the northern hemisphere is already reshaping the biotech […] December 17, 2020 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2019 Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential An off-the-shelf, gene edited CAR T-cell therapy, developed by the French biotech Cellectis, could be used to tackle solid tumors, which have so far been beyond the reach of other CAR T-cell therapies. The approved CAR T-cell therapies Kymriah and Yescarta contain genetically modified immune T-cells that can fight certain types of blood cancer. However, […] November 14, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2018 French Biotech Develops a New Generation of Safer CAR-T Cells Cellectis is developing a new type of chimeric antigen receptor that could improve the production and safety of CAR-T cell therapies generated from both patient and donor cells. Cellectis, a French biotech focused on developing CAR-T therapies from donor cells, has published a study in the journal Scientific Reports describing technological advances that could improve the […] June 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2018 French CAR-T Developer Raises $164M Despite a Challenging Road Cellectis has raised $164M (€132M) in a follow-on offering to further develop its CAR-T technology in clinical trials, despite having mixed results in the technology’s development up until now. Cellectis, based in Paris, has closed a follow-on offering on NASDAQ, raising a total of around $164M (€132M). The funding will be used to further continue clinical development […] April 11, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 13 Mar 2018 The Most Important Battle in Gene Editing: CRISPR versus TALEN Despite all the hype, CRISPR is still not in the clinic as a standalone therapy or part of another. So where is it in biotech? CRISPR needs no introduction. Since the gene editing technology first entered the spotlight in 2012 with the promise of revolutionizing gene editing, it has made headlines as the subject of a furious […] March 13, 2018 - 6 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2018 French Biotech Gets a CRISPR Patent for CAR-T Research Update (16/02/2018): On top of the European patent it got last July, Cellectis now also has two US patents to use CRISPR technology to make CAR-T cells. Cellectis has said it will offer licenses to companies that want to use CRISPR gene editing in T cells. Not just for inserting CAR antigens, but also other editions […] February 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2018 Another Huge Acquisition Sees CAR-T Stocks Jump – Except for Celyad Most CAR-T stocks rose on the news that Big Biotech Celgene has plans to acquire Juno: Cellectis rides the wave but Celyad misses it. Shortly after the mega-acquisition of Kite by Gilead, the second prettiest girl at the CAR-T party, Juno Therapeutics, has accepted the advances of Celgene in a $9Bn (€7.4Bn) acquisition. This represents a bullish […] January 23, 2018 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 17 Jan 2018 An Update on What’s New in the French Biotech Industry Here’s a closer look at the French biotech ecosystem in 2017, which remains one the leading industries in Europe along with Germany and the UK. France’s biotech ecosystem is relatively dynamic and well-developed. Young companies harboring exciting technology are encouraged into the industry by support from Bpifrance, i-LAB, and iBionext. Once a company gets off the ground, France is […] January 17, 2018 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email